Likewise, both groups (II & III) show a significant (p < 0.05) decline in A.I compared to group I. This improved dyslipidemia suggests that EPO-based SDs have the potential to overcome severities, even those prompted by the simultaneous consumption of DRF. Here, EPO is linked to metabolic syndrome.